Skip to main content
DGX
NYSE Industrial Applications And Services

Quest Diagnostics Reports Strong Q4 & FY25 Results, Boosts Dividend 7.5%, and Authorizes $1 Billion Share Buyback

Analysis by Wiseek AI
Sentiment info
Positive
Importance info
8
Price
$194.9
Mkt Cap
$21.275B
52W Low
$157.2
52W High
$197.55
Market data snapshot near publication time

Summary

Quest Diagnostics reported strong Q4 and full-year 2025 financial results, provided positive 2026 guidance, increased its quarterly dividend by 7.5%, and authorized an additional $1 billion for share repurchases.


Key Events

  • Strong Q4 and Full Year 2025 Financial Results

    Reported fourth quarter revenues of $2.81 billion (up 7.1%) and full year revenues of $11.04 billion (up 11.8%), with double-digit growth in both reported and adjusted diluted EPS for the full year.

  • Positive Full Year 2026 Guidance

    Projected full year 2026 revenues between $11.70 billion and $11.82 billion, and adjusted diluted EPS between $10.50 and $10.70, reflecting continued confidence in business strengths.

  • Quarterly Dividend Increased by 7.5%

    The Board of Directors authorized an increase in the quarterly cash dividend from $0.80 to $0.86 per share, marking the 15th consecutive year of dividend increases.

  • Additional $1 Billion Share Repurchase Authorization

    The company increased its share repurchase authorization by $1 billion, bringing the total available for repurchase to approximately $1.4 billion, demonstrating a significant commitment to returning capital to shareholders.


Analysis

Quest Diagnostics announced robust financial performance for the fourth quarter and full year 2025, coupled with an optimistic outlook for 2026. The company's commitment to shareholder returns is evident through a significant 7.5% increase in its quarterly dividend, marking the 15th consecutive year of dividend growth. Furthermore, the Board authorized an additional $1 billion for its share repurchase program, bringing the total available authorization to approximately $1.4 billion. These actions, alongside strong operational results, signal management's confidence in the company's financial health and future growth prospects, especially as the stock trades near its 52-week high.

At the time of this filing, DGX was trading at $194.90 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $21.3B. The 52-week trading range was $157.20 to $197.55. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DGX - Latest Insights

DGX
May 08, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $187.39
Real-time Price: $203.06 info
Change: +$15.67 (+8%) info
Market Cap: $22.478B info
DGX
Apr 27, 2026, 4:17 PM EDT
Filing Type: FWP
Importance Score:
7
Price at Filing: $196.63
Real-time Price: $203.06 info
Change: +$6.43 (+3%) info
Market Cap: $22.478B info
DGX
Apr 21, 2026, 6:48 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $201.00
Real-time Price: $203.06 info
Change: +$2.06 (+1%) info
Market Cap: $22.478B info
DGX
Apr 21, 2026, 6:47 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $198.80
Real-time Price: $203.06 info
Change: +$4.26 (+2%) info
Market Cap: $22.478B info
DGX
Mar 12, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $200.88
Real-time Price: $203.06 info
Change: +$2.18 (+1%) info
Market Cap: $22.478B info
DGX
Feb 26, 2026, 4:38 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $211.10
Real-time Price: $203.06 info
Change: -$8.04 (-4%) info
Market Cap: $22.478B info
DGX
Feb 10, 2026, 6:53 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $194.90
Real-time Price: $203.06 info
Change: +$8.16 (+4%) info
Market Cap: $22.478B info
DGX
Jan 12, 2026, 4:37 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $174.48
Real-time Price: $203.06 info
Change: +$28.58 (+16%) info
Market Cap: $22.478B info